Who We Are

Member Companies

VP, Research and Head of Small Molecule Therapeutic Discovery (SMTD), Amgen

Senior Vice President of Virology, Gilead

Global Public Health R&D, Johnson & Johnson

Head, Technology Licensing & Collaborations, AbbVie

Kumar Singh Saikatendu, PhD

Head, Lipid Nanoparticle Platform, Takeda Pharmaceuticals

Development Unit Head, In-Market Brands and Global Health, Novartis

VP, Global Head Infectious Diseases, Roche Pharma Research and Early Development

Senior Vice President of Virology, Gilead

VP, Global Head Infectious Diseases, Roche Pharma Research and Early Development

Health Policy and Engagement, Johnson & Johnson

Executive Director of Global Health, IFPMA

Partner, Ropes & Gray LLP

Elliott Levy, MD

Co-founder, INTREPID

John Pottage, MD

Scientific Consultant, INTREPID

Nina serves as the secretariat of the INTREPID Alliance with the responsibility of implementing the activities endorsed by the Board.

The INTREPID Alliance, Inc was registered as a Delaware non-stock corporation in April 2021, to provide a framework for start-up activities.

The Board, consisting of 7 founding member companies was elected on May 19, 2022, and terms of reference were agreed.

For more information and membership inquiries contact nina@intrepidalliance.com.